Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events

Wataru Ohashi, Hiroshi Tanaka

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost-benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet. The purpose of this study is to investigate advantages obtained by introducing PGx in clinical trials. Particularly, taking Warfarin as an example, we investigate benefits of Enrichment effect that raises response rate of the drug by PGx. When response rate is raised by only 5%, cost of a clinical trial can be reduced to about 40% of a conventional clinical trial. Furthermore, since period necessary for a trial also can be reduced, development period can be shortened by about 750 days. In summary, PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole.

Original languageEnglish
Pages (from-to)701-707
Number of pages7
JournalJournal of Medical Systems
Volume34
Issue number4
DOIs
Publication statusPublished - 2010 Aug 1

Keywords

  • Clinical trials
  • Cost-effective
  • Personalized medicines
  • Pharmacogenomics
  • SNPs
  • Warfarin

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Information Systems
  • Health Informatics
  • Health Information Management

Fingerprint Dive into the research topics of 'Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events'. Together they form a unique fingerprint.

Cite this